Once-daily versus thrice-daily administration of netilmicin in combination therapy ofPseudomonas aeruginosa infection in a man-adapted neutropenic animal model

1989 ◽  
Vol 8 (3) ◽  
pp. 233-237 ◽  
Author(s):  
A. U. Gerber ◽  
S. Kozak ◽  
C. Segessenmann ◽  
U. Flückiger ◽  
T. Bangerter ◽  
...  
Keyword(s):  
Animal Model ◽  
Combination Therapy ◽  
Daily Administration ◽  
Once Daily

scholarly journals Efficacy of SCH27899 in an Animal Model of Legionnaires' Disease Using Immunocompromised A/J Mice

2000 ◽  
Vol 44 (5) ◽  
pp. 1333-1336 ◽  
Author(s):  
Joan K. Brieland ◽  
David Loebenberg ◽  
Fred Menzel ◽  
Roberta S. Hare
Keyword(s):  
Animal Model ◽  
Murine Model ◽  
Legionella Pneumophila ◽  
Immunocompromised Host ◽  
Lung Infection ◽  
Cortisone Acetate ◽  
Contrast Administration ◽  
Once Daily ◽  
Legionnaires Disease ◽  
Lung Infections

ABSTRACT The efficacy of SCH27899, a new everninomicin antibiotic, against replicative Legionella pneumophila lung infections in an immunocompromised host was evaluated using a murine model of Legionnaires' disease. A/J mice were immunocompromised with cortisone acetate and inoculated intratracheally with L. pneumophilaserogroup 1 (105 CFU per mouse). At 24 h postinoculation, mice were administered either SCH27899 (6 to 60 mg/kg [MPK] intravenously) or a placebo once daily for 5 days, and mortality and intrapulmonary growth of L. pneumophila were assessed. In the absence of SCH27899, there was 100% mortality inL. pneumophila-infected mice, with exponential intrapulmonary growth of the bacteria. In contrast, administration of SCH27899 at a dose of ≥30 MPK resulted in ≥90% survival of infected mice, which was associated with inhibition of intrapulmonary growth ofL. pneumophila. In subsequent studies, the efficacy of SCH27899 was compared to ofloxacin (OFX) and azithromycin (AZI). Administration of SCH27899, OFX, or AZI at a dose of ≥30 MPK once daily for 5 days resulted in ≥85% survival of infected mice and inhibition of intrapulmonary growth of the bacteria. However, L. pneumophila CFU were recovered in lung homogenates following cessation of therapy with all three antibiotics. These studies demonstrate that SCH27899 effectively prevents fatal replicativeL. pneumophila lung infection in immunocompromised A/J mice by inhibition of intrapulmonary growth of the bacteria. However, in this murine model of pulmonary legionellosis, SCH27899, like OFX and AZI, was bacteriostatic.

Once-Daily Administration of Antiretrovirals

2003 ◽  
Vol 42 (14) ◽  
pp. 1179-1191 ◽  
Author(s):  
Anne-Marie Taburet ◽  
Sabine Paci-Bonaventure ◽  
Gilles Peytavin ◽  
Jean-Michel Molina
Keyword(s):  
Daily Administration ◽  
Once Daily

scholarly journals Design and Evaluation Of Metronidazole Vaginal Tablet For Once Daily Administration

2019 ◽  
Vol 12 (04) ◽  
pp. 244-265
Author(s):  
Krishnaveni Manubolu ◽  
K. Sruthi ◽  
M. Sreenivasulu
Keyword(s):  
Daily Administration ◽  
Once Daily ◽  
Vaginal Tablet

Antitumor Efficacy of Combination Therapy Consisting of S-1, Leucovorin, and Oxaliplatin against Human Gastric Cancer Xenografts

Chemotherapy ◽  
2018 ◽  
Vol 63 (1) ◽  
pp. 46-52
Author(s):  
Hideki Nagase ◽  
Fumio Nakagawa ◽  
Junji Uchida
Keyword(s):  
Gastric Cancer ◽  
Combination Therapy ◽  
Tumor Volume ◽  
Preclinical Study ◽  
Antitumor Efficacy ◽  
Human Gastric Cancer ◽  
Antitumor Activities ◽  
Once Daily ◽  
Xenograft Models

Background/Aim: A phase 3 trial of S-1, leucovorin (LV), and oxaliplatin for treating gastric cancer is now underway. However, the antitumor efficacy of the combination has not yet been examined in an in vivo preclinical study. This study examined the antitumor efficacy of combination therapy consisting of S-1, LV, and oxaliplatin against 4 human gastric cancer xenografts: NUGC-4, St-40, SC-2, and SC-4. Methods: The antitumor efficacy was evaluated using human gastric cancer xenograft-bearing nude mice. S-1 and LV were administered orally once daily on days 1-7 at doses of 6.9 and 10 mg/kg, respectively. Oxaliplatin was administered intravenously at a dose of 8.3 mg/kg on day 1. The tumor volume was measured on day 15, and the relative tumor volume (RTV) was calculated. Results: In all 4 xenograft models, S-1 alone and oxaliplatin alone, but not LV alone, had significant antitumor activities (p < 0.001). Combination therapy consisting of S-1 and LV resulted in a significantly smaller RTV than S-1 alone (p < 0.001). Combination therapy consisting of S-1 and oxaliplatin also resulted in a significantly smaller RTV than either S-1 alone (p < 0.001) or oxaliplatin alone (p < 0.001). Furthermore, combination therapy consisting of S-1, LV, and oxaliplatin resulted in the highest antitumor activity in these models (p < 0.001 vs. S-1 + LV; p < 0.001 or p = 0.003 vs. S-1 + oxaliplatin). Conclusion: Combination therapy consisting of S-1, LV, and oxaliplatin administered according to a 1-week-on/1-week-off schedule may be useful for the treatment of patients with gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document